NeuroPace's implantable neurostimulator will receive new technology add-on payments from the federal Centers for Medicare & Medicaid Services in recognition of its clinical benefits compared to older therapies for the treatment of uncontrolled epilepsy in adults.
The $40 million Department of Defense research program into restoring memory will use NeuroPace's implantable neurostimulator, a move that the company said could help it expand the product's indications beyond epilepsy.
As interest in NeuroPace's new RNS neuromodulation antiepilepsy implant ramps up, The New York Times tracked down some of the patients who use the device and have experienced major improvements in their quality of life.
California's NeuroPace gained the FDA's long-awaited signoff for its antiepilepsy neurostimulation implant, capping years of development and testing.
California's NeuroPace raised $18 million of a sought-after $50 million in its latest funding round, cash that should help speed along the path to market for its anti-epilepsy neurostimulation device.
NeuroPace is on the path to FDA approval for its anti-epilepsy neurostimulation device, winning unanimous backing from the agency's neurological devices panel.
By now, the device-tax woes of major companies are well-told, but med tech startups, eking out small profits or taking losses, might suffer the worst from the 2.3% charge.
The Wall Street Journal has put together its list of the top 50 venture-backed companies most likely to do great things. The good news is that Achaogen, a San Francisco-based antibiotics company, and Acceleron, the Cambridge, MA-based tissue- and muscle-building company, are both on the list.